Information Provided By:
Fly News Breaks for December 12, 2016
AKRX
Dec 12, 2016 | 12:20 EDT
Craig-Hallum analyst Matt Hewitt reiterates a Buy rating and $36 price target on Akorn after the company said the FDA re-inspected its Decatur manufacturing facility and had no 483 observations. The news "removes a significant overhang" and the shares should "march higher" as a result, Hewitt tells investors in a research note. The analyst expects Akorn to receive "several" near-term approvals.
News For AKRX From the Last 2 Days
There are no results for your query AKRX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.